7XB0 Stock Chart & Stats
€0.85
-€0.01(-1.17%)
―
--
Day’s Range― - ―
52-Week Range€0.45 - €3.53
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00
Market Cap
€19.23M
Enterprise Value€232.63
Total Cash (Recent Filing)€49.50M
Total Debt (Recent Filing)€63.71M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume5
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€15.89M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityThe currently low leverage and substantial equity base provide financial flexibility relative to many biotechnology companies. Deleveraging from the high levels seen in 2023–2024 may reduce balance-sheet pressure and help preserve capacity for development and commercialization activities over the next several quarters.
Recent TTM Revenue GrowthRecent TTM revenue growth indicates that the business retains some ability to generate commercial momentum despite earlier annual declines. If maintained, improving sales can strengthen operating leverage, support partner economics, and provide a broader revenue base for the biosimilar portfolio.
Biosimilar And Partnering ModelThe biosimilar and partnering model targets lower-cost alternatives to established biologics while allowing development, regulatory, manufacturing, or commercialization activities to be shared with partners. This can broaden market access and create multiple potential revenue streams as programs advance.
Bears Say
Persistent Operating Cash BurnDeeply negative operating and free cash flow means the company is not currently funding operations and investment internally. Continued cash consumption can require financing or use of balance-sheet resources, limiting strategic flexibility and increasing pressure to deliver successful program outcomes.
Ongoing Operating LossesOngoing operating losses show that the core business has not yet reached a sustainable earnings base. Persistent losses can erode equity over time, constrain reinvestment capacity, and make future profitability dependent on successful launches, approvals, partnerships, or meaningful cost improvement.
Volatile And Declining Annual RevenueThe annual revenue declines and volatility indicate limited consistency in the company’s commercial performance. Unstable sales make forecasting and resource planning more difficult, while weaker revenue periods can amplify cash burn and delay the operating scale needed to absorb fixed development costs.
Xbrane Biopharma AB News
7XB0 FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was €0.45 and its highest was €3.52 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €19.23M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Oct 30, 2026 which is in 27 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Jul 17, 2026. The company reported -€0.049 earnings per share for the quarter.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Undervalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -€0.049 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in DE:7XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Technical Analysis
Hansa Biopharma AB
―
Alligator Bioscience AB
―
BioInvent International AB
―
Elicera Therapeutics AB
―
Cantargia AB
―